FindTrial
Sign In

COMPARISON OF MARMA THERAPY AND MUKTA VATI IN THE TREATMENT OF STAGE I HYPERTENSION

A MULTI-CENTRE STUDY: COMPARISON OF MARMA THERAPY AND MUKTA VATI IN THE TREATMENT OF STAGE I HYPERTENSION

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026313
Enrollment
30
Registered
2020-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Role of marma therapy and mukta vati in stage 1 hypertension: In first stage of hypertensive patients we will give mukta vati 300 mg B.D along with marma therapy thrice a day Control In

Sponsors

Rishikul campus UAU hardwar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with be enrolled with 1 hypertension (130-139/80-89 mmhg) Hypertensive patients who are drug naive Normal LV function

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Normalize the BP 120/80mmhgTimepoint: 3 months—

Secondary

MeasureTime frame
Relieve in symptomsTimepoint: 3 months—

Countries

India

Contacts

Public ContactUrvashi

rishikul ayurvedic college hardwar

mrityunjaymission@gmail.com9897523499

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026